Loading stock data…
AEMD
$1.94-0.09 (-4.43%)
After Hours$1.94+0.00 (+0.00%)· Last close Jun 9
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aethlon Medical, Inc. in the Healthcare sector is trading at $1.94. Wall Street consensus targets $4.75 (2 analysts), implying a +144.8% move over the next 12 months. The stock is currently near its 52-week low of $1.36, remaining 52.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +144.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.94
Potential Downside
0%
Whystock Fair Value$1.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for ap...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-171.64%
Volume
Today's trading volume
129,594
Recent News
Aethlon Medical Inc (AEMD) Q3 2026 Earnings Call Highlights: Progress in Oncology Trials and ...
Aethlon Medical Inc (AEMD) reports significant strides in oncology trials and research platform expansion, despite facing increased operating expenses.
Aethlon Medical, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aethlon Medical, Inc.'s Q3 2026 earnings call
Aethlon Medical announces pricing of $4.5M common stock, warrant offering
Aethlon Medical (AEMD) announced the pricing of a public offering of an aggregate of 5M shares of its common stock and warrants to purchase up to 5M shares of common stock at a combined public offering price of 90c per share and accompanying warrant. The warrants will have an exercise price of 90c per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date. The closing of the offering is expected to occur on or about September 5
BC-Most Active Stocks
Raytech Holding Ltd. 19,129,535 2.735
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Aethlon Medical Inc (AEMD) reports progress in its Australian trial, cost-saving measures, and plans for future funding amid strategic shifts.